sb 203580 has been researched along with sevoflurane in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (sevoflurane) | Trials (sevoflurane) | Recent Studies (post-2010) (sevoflurane) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 7,131 | 2,150 | 3,238 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, ZG; Dong, XW; Guo, SX; Liu, Y; Wang, S; Wang, ZP; Zeng, YM | 1 |
| Gu, M; Liang, H; Wang, H; Wen, X; Yang, C; Zhou, Q | 1 |
2 other study(ies) available for sb 203580 and sevoflurane
| Article | Year |
|---|---|
Duplicate preconditioning with sevoflurane in vitro improves neuroprotection in rat brain via activating the extracellular signal-regulated protein kinase.
Topics: Action Potentials; Anesthetics, Inhalation; Animals; Butadienes; CA1 Region, Hippocampal; Cell Hypoxia; Electrophysiology; Extracellular Signal-Regulated MAP Kinases; Glucose; Imidazoles; Methyl Ethers; Neuroprotective Agents; Nitriles; Organ Culture Techniques; Oxygen; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; Rats, Sprague-Dawley; Sevoflurane; Time Factors | 2010 |
Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway.
Topics: Anesthetics, Inhalation; Cell Line, Tumor; Cell Movement; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase Inhibitors; Methyl Ethers; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Sevoflurane | 2012 |